Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Rating of “Hold” from Analysts

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been assigned an average rating of “Hold” from the seven analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $53.60.

A number of equities analysts have issued reports on TVRD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. BTIG Research reaffirmed a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. Finally, Wall Street Zen downgraded shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds have recently bought and sold shares of the company. American Financial Group Inc. bought a new stake in shares of Tvardi Therapeutics during the 4th quarter worth $962,000. Vestal Point Capital LP bought a new stake in Tvardi Therapeutics in the 3rd quarter valued at about $6,508,000. Geode Capital Management LLC bought a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $2,617,000. Invesco Ltd. bought a new stake in Tvardi Therapeutics in the 3rd quarter valued at about $3,219,000. Finally, Renaissance Technologies LLC raised its stake in Tvardi Therapeutics by 246.3% in the 4th quarter. Renaissance Technologies LLC now owns 104,500 shares of the company’s stock valued at $449,000 after acquiring an additional 74,325 shares during the period. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Trading Down 0.6%

NASDAQ TVRD opened at $3.57 on Friday. The company has a fifty day simple moving average of $3.43 and a 200 day simple moving average of $3.85. Tvardi Therapeutics has a 12-month low of $2.75 and a 12-month high of $43.65. The company has a market cap of $33.49 million, a P/E ratio of -1.15 and a beta of 0.30.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Sell-side analysts predict that Tvardi Therapeutics will post -2.1 EPS for the current year.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.